1096586

Carglumic Acid

United States Pharmacopeia (USP) Reference Standard

Manufacturer: Sigma Aldrich

CAS Number: 1188-38-1

Synonym(S): N-Carbamyl-L-glutamic acid

Select a Size

Pack Size SKU Availability Price
200 MG 1096586-200-MG In Stock ₹ 49,437.78

1096586 - 200 MG

₹ 49,437.78

In Stock

Quantity

1

Base Price: ₹ 49,437.78

GST (18%): ₹ 8,898.80

Total Price: ₹ 58,336.58

grade

pharmaceutical primary standard

manufacturer/tradename

USP

application(s)

pharmaceutical

format

neat

storage temp.

2-8°C

SMILES string

NC(=O)N[C@@H](CCC(O)=O)C(O)=O

InChI

1S/C6H10N2O5/c7-6(13)8-3(5(11)12)1-2-4(9)10/h3H,1-2H2,(H,9,10)(H,11,12)(H3,7,8,13)/t3-/m0/s1

InChI key

LCQLHJZYVOQKHU-VKHMYHEASA-N

Gene Information

human ... CPS1(1373)

Other Options

Image Product Name Manufacturer Price Range
eMolecules​ Ambeed / (2S)-2-(Carbamoylamino)pentanedioic acid / 250mg / 525179410 / A304788 / / 1188-38-1 / MFCD00047874 / 190.155 / C6H10N2O5
-- ₹ 2,148.46
Carglumic Acid
-- ₹ 19,961.30
N-Carbamyl-L-glutamic acid
-- ₹ 21,725.78
Carglumic Acid
-- ₹ 890.00 - ₹ 34,710.00
1188-38-1 | N-Carbamyl-l-glutamic acid
-- ₹ 1,513.00 - ₹ 38,537.00

Related Products

Img

Sigma Aldrich

1133842

United States Pharmacopeia (USP) Re...

Img

Sigma Aldrich

1042500

United States Pharmacopeia (USP) Re...

Img

Sigma Aldrich

1133853

United States Pharmacopeia (USP) Re...

Img

Sigma Aldrich

1162308

United States Pharmacopeia (USP) Re...

Description

  • General description: This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including MSDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
  • Application: Efficacy of Carglumic Acid in Nutritional Management of N-Acetylglutamate Synthase Deficiency: A study evaluated the effectiveness of Carglumic Acid in the nutritional management of patients with N-Acetylglutamate Synthase deficiency, showing significant improvements in patient outcomes (Singh et al., 2024).Real-World Use of Carglumic Acid for Organic Acidurias: An observational study highlighted the real-world application of Carglumic Acid in treating methylmalonic and propionic acidurias, demonstrating beneficial effects in metabolic management (Yap et al., 2024).Management of Hyperammonemia in Postpartum Women: Research documented a case of partial N-acetyl glutamate synthase deficiency presenting as postpartum hyperammonemia, with management strategies involving Carglumic Acid (Abou Haidar et al., 2023).Genetic Insights from Carglumic Acid Treatment: Research on novel compound heterozygote variants in the CPS1 gene emphasized the lessons learned from clinical management using Carglumic Acid, impacting late onset carbamoyl phosphate synthetase 1 deficiency (Lin et al., 2022).
  • Analysis Note: These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​
  • Other Notes: USP issued SDS can be found here.

SAFETY INFORMATION

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable